SNY
Press Release: Sarclisa is the first anti-CD38 treatment approved in China for patients with newly diagnosed multiple myeloma ineligible for transplant
Sarclisa is the first anti-CD38 treatment approved in China for patients with newly diagnosed multiple myeloma ineligible for transplant
Read moreDetails
SNY’s Subcutaneous Sarclisa Outperforms IV Formulation in Cancer Study
Sanofi's Sarclisa SC formulation shows non-inferiority versus Sarclisa IV infusion in a late-stage study for treating relapsed, refractory multiple myeloma.
Read moreDetails
Press Release: New Sarclisa subcutaneous formulation met co-primary endpoints in the IRAKLIA phase 3 study in multiple myeloma
New Sarclisa subcutaneous formulation met co-primary endpoints in the IRAKLIA phase 3 study in multiple myeloma Sarclisa SC formulation added...
Read moreDetails
Sanofi Down 10% in 3 Months: How Should You Play the Stock?
Sanofi's SNY stock has declined 10.2% in the past three months. However, a lot of this price decline was due...
Read moreDetails